NA
IONS icon

Neuburgh Advisers’s Ionis Pharmaceuticals IONS Stock Holding History

Neuburgh Advisers’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-18,394
Closed -$1.18M – 929
2019
Q2 		$1.18M Buy
18,394
+15,674
+576% +$1.11M 0.04% 302
2019
Q1 		$221K Buy
+2,720
New +$175K 0.01% 651

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Neuburgh Advisers's IONS Position: Q3 2019 in Review

Neuburgh Advisers sold out of Ionis Pharmaceuticals (IONS) in Q3 2019, closing a stake of 18,394 shares — an estimated $1.18M sold.

Neuburgh Advisers first reported a position in IONS in Q1 2019 and held it in 2 quarters. The position peaked at $1.18M in Q2 2019. 369 funds tracked by Wall St. Rank hold IONS as of Q3 2019.

  • Neuburgh Advisers reported no remaining Ionis Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Neuburgh Advisers sold 18,394 Ionis Pharmaceuticals shares in Q3 2019, an estimated $1.18M.
  • Neuburgh Advisers first reported a position in Ionis Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Neuburgh Advisers's Ionis Pharmaceuticals position peaked at $1.18M in Q2 2019.
  • 369 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.